Company / Operating Cash Flow
TENAX THERAPEUTICS, INC. Operating Cash Flow History
FY2012-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$14.8M
FY2025
5-year range
-$14.8M / -$4.9M
FY2021-FY2025
Trend
-150.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$9M to -$15M over the past 9 years.
Based on SEC 10-K filings.
-$15M in FY2025.
Declined from -$9M to -$15M over the past 9 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 150.9% year-over-year.
- Peak operating cash flow was recorded in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.24 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$14.8M | -150.9% |
| FY2024 | -$5.9M | +36.3% |
| FY2016 | -$9.3M | +0.0% |
| FY2015 | -$9.3M | -88.2% |
| FY2014 | -$4.9M | +40.6% |
| FY2013 | -$8.3M | +1.5% |
| FY2012 | -$8.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026